Context Therapeutics’ (CNTX) Buy Rating Reiterated at HC Wainwright

Context Therapeutics (NASDAQ:CNTXGet Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $5.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 150.00% from the stock’s previous close.

A number of other equities analysts have also issued reports on CNTX. Piper Sandler Companies initiated coverage on Context Therapeutics in a report on Thursday, May 16th. They issued an “overweight” rating and a $4.50 price objective for the company. Maxim Group raised their price objective on Context Therapeutics from $4.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, May 9th. Finally, Piper Sandler assumed coverage on Context Therapeutics in a research report on Thursday, May 16th. They issued an “overweight” rating and a $4.50 price target for the company.

Read Our Latest Research Report on CNTX

Context Therapeutics Price Performance

CNTX traded up $0.06 on Wednesday, reaching $2.00. The company’s stock had a trading volume of 118,239 shares, compared to its average volume of 375,155. The business’s 50 day moving average is $1.89 and its 200 day moving average is $1.43. Context Therapeutics has a 1 year low of $0.77 and a 1 year high of $2.24. The stock has a market cap of $150 million, a price-to-earnings ratio of -1.50 and a beta of 2.30.

Context Therapeutics (NASDAQ:CNTXGet Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.15. As a group, research analysts forecast that Context Therapeutics will post -0.36 earnings per share for the current fiscal year.

Institutional Trading of Context Therapeutics

A hedge fund recently bought a new stake in Context Therapeutics stock. Opaleye Management Inc. bought a new position in shares of Context Therapeutics Inc. (NASDAQ:CNTXFree Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 975,000 shares of the company’s stock, valued at approximately $1,102,000. Opaleye Management Inc. owned 6.11% of Context Therapeutics as of its most recent filing with the Securities and Exchange Commission. 14.03% of the stock is currently owned by institutional investors and hedge funds.

About Context Therapeutics

(Get Free Report)

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.

Recommended Stories

Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.